MA50899A - Composés utiles pour l'inhibition de cdk7 - Google Patents

Composés utiles pour l'inhibition de cdk7

Info

Publication number
MA50899A
MA50899A MA050899A MA50899A MA50899A MA 50899 A MA50899 A MA 50899A MA 050899 A MA050899 A MA 050899A MA 50899 A MA50899 A MA 50899A MA 50899 A MA50899 A MA 50899A
Authority
MA
Morocco
Prior art keywords
compounds useful
cdk7 inhibition
cdk7
inhibition
compounds
Prior art date
Application number
MA050899A
Other languages
English (en)
Other versions
MA50899B1 (fr
Inventor
David Andrew Coates
Carlos Montero
Bharvin Kumar Rameschandra Patel
David Michael Remick
Vipin Yadav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2018/060025 external-priority patent/WO2019099298A1/fr
Publication of MA50899A publication Critical patent/MA50899A/fr
Publication of MA50899B1 publication Critical patent/MA50899B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA50899A 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7 MA50899B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
PCT/US2018/060025 WO2019099298A1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Publications (2)

Publication Number Publication Date
MA50899A true MA50899A (fr) 2020-09-23
MA50899B1 MA50899B1 (fr) 2022-10-31

Family

ID=60484312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50899A MA50899B1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Country Status (2)

Country Link
AR (1) AR113817A1 (fr)
MA (1) MA50899B1 (fr)

Also Published As

Publication number Publication date
MA50899B1 (fr) 2022-10-31
AR113817A1 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
EP3519816A4 (fr) Composés pour l'augmentation de la plasticité neuronale
EP3442488A4 (fr) Compositions pour l'application topique de composés
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
EP3820860A4 (fr) Composés pyridazineg pour inhiber nav1.8
EP3446194A4 (fr) Raccourcis d'application pour carplay
ME03334B (fr) Composés hétéroaryle d'inhibition de la kinase
EP3465554A4 (fr) Agents de conversation personnalisés pour résidents d'établissement
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
EP3630078A4 (fr) Agents pour chimio-embolisation
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3700516A4 (fr) Inhibiteurs de l'induction de dux4 pour la régulation de la fonction musculaire
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
MA47420A (fr) Composés inhibiteurs d'oga
EP3476478A4 (fr) Composition pour l'élimination de composés soufrés
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
EP3348557A4 (fr) Composé pour traiter ou prévenir l'hyperuricémie ou la goutte
EP3627918C0 (fr) Radiorecherche d'extension de couverture pour ec-gsm
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
EP3403655A4 (fr) Composition pour augmenter l'expression de pgc-1
EP3942971A4 (fr) Cintre pour vêtements
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3443969A4 (fr) Composition d'amélioration de la fonction cérébrale pour nouveau-nés